Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3439-3442

  Adabala, Madhuri ^a   Jhaveri, Kenar D ^a   Gitman, Michael ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

haemodialysis; hyperkalaemia; octreotide; sulphonylurea agents

Indexed keywords

ALLOPURINOL; AMIODARONE; ATENOLOL; CALCITRIOL; ESOMEPRAZOLE; FOLIC ACID; GLIPIZIDE; GLUCONATE CALCIUM; GLUCOSE; INSULIN; MULTIVITAMIN; OCTREOTIDE; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SALBUTAMOL; SEVELAMER; SULFONYLUREA; WARFARIN;

ADULT; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY WARD; FOCAL GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GOUT; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; HYPERKALEMIA; HYPERVOLEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LABORATORY TEST; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; POTASSIUM TRANSPORT; PRIORITY JOURNAL; THORAX PAIN; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE REPAIR;

HUMANS; HYPERKALEMIA; HYPOGLYCEMIA; INSULIN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OCTREOTIDE; RENAL DIALYSIS; SULFONYLUREA COMPOUNDS;

EID: 77957224453     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq381     Document Type: Article

References (22)

1. Harrigan RA, Nathan MS, Beattie P. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38: 68-78
2. Shorr RI, Ray WA, Daugherty JR et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751-755
3. Stahl M, Berger W. High incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long acting versus short acting sulfonylureas. Diabet Med 1999; 16: 586-590
4. Boyle PJ, Justice K, Krentz AJ et al. Octreotide reverses hyperinsu-linemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76: 752-756
5. Arem R. Hypoglycemia associated with renal failure. Endocrinol Metab Clin North Am 1989; 18: 103-121
6. Palatnick W, Meatherall RC, Tenenbein M. Clinical spectrum of sul-fonylurea overdose and experience with diazoxide therapy. Arch Intern Med 1991; 151: 1859-1862
7. Malmström R. Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. Atherosclerosis 1999; 146: 381-390
8. McKillop G, Fallon M, Slater SD. Possible interaction between hep-arin and a sulphonylurea as cause of prolonged hypoglycaemia? Br Med J (Clin Res Ed) 1986; 293: 1073
9. Gonzalez RR, Zweig S, Rao J et al. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure. Endocr Pract 2007; 13: 417-423
10. Flomenbaum NE, Goldfrank LR, Hoffman RS et al. Goldfrank's Toxicologic Emergencies 8th edn, 770-774, McGraw-Hill
11. Gul M, Cander B, Girisgin S et al. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther 2006; 23: 878-884
12. Green RS, Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea induced hypoglycemia. J Emerg Med 2003; 25: 283-287
13. Krentz AJ, Boyle PJ, Justice KM et al. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diab Care 1993; 16: 184-186
14. Barrons RW. Octreotide in hyperinsulinism. Ann Pharmacother 1997; 31: 237-241
15. Osei K, O'Dorisio TM. Malignant insulinomas: effects of a somato-statin analog (compound 201-995) on serum glucose, growth, and gas-tro-entero- pancreatic hormones. Ann Intern Med 1985; 103: 223-225
16. Alberts AS, FalksonG.Rapid reversaloflife-threateninghypoglycemia with a somatostatin analogue (octreotide). A case report. S Afr Med J 1988; 74: 75-76
17. Apak RA, Yurdakok M, Oran O et al. Preoperative use of octretide in a newborn with persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr Endocrinol Metab 1998; 11: 143-145
18. Sargent AI, Overton CC, Kuwik RJ et al. Octreotide-induced hyper-kalemia. Pharmacotherapy 1995; 14: 497-501
19. Brown RO, Hamrick KD, Dickerson RN et al. Hyperkalemia secondary to concurrent pharmacotherapy in a patient receiving home par-enteral nutrition. J Parenter Enteral Nutr 1996; 20: 429-432
20. Sharma AM, Thieda HM, Keller F. Somatostatin-induced hyperkale-mia in a patient on maintenance hemodialysis. Nephron 1991; 59: 445-448
21. Gul M, Cander B, Ahmet AK et al. Successful treatment of prolonged sulfonylurea-induced hypoglycemia with octreotide in a patient with chronic renal failure. Turkiye Klinikleri J Med Sci 2008; 28: 100-103
22. Yavari A, Ostermann M, Maclean D et al. Octreotide for relapsing sulfonylurea-induced hypoglycemia in a dialysis patient. Dial Transplant 2007; 36: 221-226